Targeting BCMA in Multiple Myeloma.

IF 2.7 3区医学 Q2 HEMATOLOGY Current Hematologic Malignancy Reports Pub Date : 2021-10-01 Epub Date: 2021-08-25 DOI:10.1007/s11899-021-00639-z

Carlyn Rose Tan, Urvi A Shah

{"title":"Targeting BCMA in Multiple Myeloma.","authors":"Carlyn Rose Tan, Urvi A Shah","doi":"10.1007/s11899-021-00639-z","DOIUrl":null,"url":null,"abstract":"Purpose of review: Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a significant number of patients still progress on current available therapies. Here, we review treatment modalities used to target BCMA in the treatment of MM, specifically antibody-drug conjugates (ADC), bispecific antibody constructs, and chimeric antibody receptor (CAR) modified T-cell therapies. We will provide an overview of therapies from these classes that have presented or published clinical data, as well as data on mechanisms of resistance to these novel agents.Recent findings: Clinical trials exploring different BCMA-targeting modalities to treat multiple myeloma are underway and demonstrate promising results. In relapsed/refractory multiple myeloma, anti-BCMA ADCs and bispecific antibody constructs are showing impressive efficacy with manageable side effect profiles. In parallel, adoptive cellular therapy has induced dramatic durable responses in multiply relapsed and refractory myeloma patients. Therapeutic approaches targeting BCMA hold significant potential in the management of multiple myeloma and will soon be incorporated in combination with current standard therapies to improve outcomes for patients with multiple myeloma. In addition, novel approaches are being evaluated to overcome resistance mechanisms to anti-BCMA therapies.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11899-021-00639-z","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hematologic Malignancy Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11899-021-00639-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/8/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 5

Abstract

Purpose of review: Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a significant number of patients still progress on current available therapies. Here, we review treatment modalities used to target BCMA in the treatment of MM, specifically antibody-drug conjugates (ADC), bispecific antibody constructs, and chimeric antibody receptor (CAR) modified T-cell therapies. We will provide an overview of therapies from these classes that have presented or published clinical data, as well as data on mechanisms of resistance to these novel agents.

Recent findings: Clinical trials exploring different BCMA-targeting modalities to treat multiple myeloma are underway and demonstrate promising results. In relapsed/refractory multiple myeloma, anti-BCMA ADCs and bispecific antibody constructs are showing impressive efficacy with manageable side effect profiles. In parallel, adoptive cellular therapy has induced dramatic durable responses in multiply relapsed and refractory myeloma patients. Therapeutic approaches targeting BCMA hold significant potential in the management of multiple myeloma and will soon be incorporated in combination with current standard therapies to improve outcomes for patients with multiple myeloma. In addition, novel approaches are being evaluated to overcome resistance mechanisms to anti-BCMA therapies.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

靶向BCMA治疗多发性骨髓瘤

回顾目的:尽管在过去十年中多发性骨髓瘤(MM)的治疗取得了相当大的进展，但仍有相当多的患者在现有的治疗方法中取得进展。在这里，我们回顾了用于靶向BCMA治疗MM的治疗方式，特别是抗体-药物偶联物(ADC)，双特异性抗体构建和嵌合抗体受体(CAR)修饰的t细胞疗法。我们将概述这些类别中已经提出或发表的临床数据的治疗方法，以及对这些新药物的耐药机制的数据。近期发现:临床试验正在探索不同bcma靶向治疗多发性骨髓瘤的方式，并显示出有希望的结果。在复发/难治性多发性骨髓瘤中，抗bcma adc和双特异性抗体结构显示出令人印象深刻的疗效和可控的副作用。与此同时，过继细胞疗法在多次复发和难治性骨髓瘤患者中诱导了显著的持久反应。针对BCMA的治疗方法在多发性骨髓瘤的治疗中具有巨大的潜力，并将很快与目前的标准治疗相结合，以改善多发性骨髓瘤患者的预后。此外，正在评估新的方法来克服抗bcma治疗的耐药机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Hematologic Malignancy Reports ONCOLOGY-HEMATOLOGY

CiteScore

6.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.

期刊最新文献

Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas. JAK Inhibitors for Myelofibrosis: Strengths and Limitations. Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals. Prognostic and Predictive Models in Myelofibrosis. Systemic Mastocytosis: State of the Art.